New antibody treatment aims to keep myeloma in check after transplant

NCT ID NCT03346135

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether daratumumab, an antibody that targets cancer cells, can improve outcomes for people with multiple myeloma after they receive a stem cell transplant. The study involves 31 participants and is currently active but not recruiting. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab (a monoclonal antibody, brand name Darzalex)
What this could lead to: If successful, this could offer a way to keep multiple myeloma from coming back longer after a stem cell transplant.
What could go wrong: This is a small, early-phase trial with only 31 people, so results may not apply to everyone. Daratumumab can cause infusion reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AA amyloidosis plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL MYELOMA SECONDARY AMYLOIDOSIS

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
Sarah Cannon Cancer Center

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.